X-PACT Immunolight (Breast Cancer, Head & Neck Cancer, Melanoma, and Sarcoma)

Purpose of this Study

We are doing this study to find out if an experimental drug and device system called X-PACT is a safe and effective treatment for various forms of cancer.

Who Can Participate?

Eligibility

Adults ages 18+ who:<ul>
<li>Have soft tissue sarcoma, melanoma, breast cancer, or head and neck cancer</li>
<li>Still have cancer after treatment with the standard therapies</li>
<li>Do not have any other treatment options left</li></ul>
For more information about who can join this study, please contact the study team at elizabeth.sachs@duke.edu

Age Range

8-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

If you join this study, you will:<ul>
<li>Be injected with the study treatment (X-PACT) five times</li>
<li>Give tumor tissue</li>
<li>Have physical exams, blood draws, and urine tests</li>
<li>Have a heart scan (ECG)</li>
<li>Have imaging scans (X-Rays, MRI and/or CT)</li></ul>
Please visit https://www.immunolight.com/patients to learn more about the study treatment.

Locations

Duke University Hospital
Other

Visit Timing

Weekdays
Evenings

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection in Patients with Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma

Principal Investigator

William
Eward

Protocol Number

PRO00105022

NCT ID

NCT04389281

Phase

I

Enrollment Status

Open to Enrollment